Literature DB >> 14647958

Modulation of nerve growth factor and choline acetyltransferase expression in rat hippocampus after chronic exposure to haloperidol, risperidone, and olanzapine.

Vinay Parikh1, Alvin V Terry, Mohammad M Khan, Sahebarao P Mahadik.   

Abstract

RATIONALE: Recently, we reported that compared to haloperidol, chronic exposure to either the risperidone (RISP) or olanzapine (OLZ) resulted in superior effects on spatial learning performance as well as the cholinergic neurons, although the mechanism for these effects was not addressed.
OBJECTIVES: The objective of this study was to investigate one plausible mechanism whereby RISP and OLZ exert superior effects on cholinergic neurons, i.e. positive effects on nerve growth factor (NGF), which is known to regulate the brain cholinergic activity as well as cognitive function. Therefore, the effects of chronic exposure to HAL, RISP, or OLZ on the expression of NGF and choline acetyltransferase (ChAT) in the hippocampus (i.e. a brain area well known to be involved in cognitive function and known to receive major cholinergic projections from the medial septum) were compared.
METHODS: Rats were treated with HAL (1 or 2 mg/kg per day), RISP (1.25 or 2.5 mg/kg per day), or OLZ (5 or 10 mg/kg per day) for 45 days in drinking water. NGF and ChAT were measured by immunohistochemistry and NGF protein was also measured by an enzyme-linked ImmunoSorbent assay.
RESULTS: Compared to controls, HAL exposure resulted in a marked reduction in NGF immunoreactivity in the hippocampal dentate gyrus (DG), CA1 and CA3 areas. In contrast, RISP did not alter, while OLZ significantly increased levels of NGF. These changes in NGF levels corresponded well with changes in ChAT immunoreactivity in the hippocampus and the medial septum.
CONCLUSIONS: These preclinical data, combined with previously published behavioral results, support the premise that OLZ and RISP, in contrast to HAL, preserve cholinergic pathways and cognitive function via superior effects on NGF expression and are thus therapeutically superior for extended use.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14647958     DOI: 10.1007/s00213-003-1669-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  48 in total

Review 1.  Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia.

Authors:  H E Spohn; M E Strauss
Journal:  J Abnorm Psychol       Date:  1989-11

2.  Effects of gonadectomy on immunoreactivity for choline acetyltransferase in the cortex, hippocampus, and basal forebrain of adult male rats.

Authors:  N Nakamura; H Fujita; M Kawata
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

3.  An analysis of the origins of the cholinergic and noncholinergic septal projections to the hippocampal formation of the rat.

Authors:  D G Amaral; J Kurz
Journal:  J Comp Neurol       Date:  1985-10-01       Impact factor: 3.215

4.  Presynaptic markers of cholinergic function in the rat brain: relationship with age and cognitive status.

Authors:  M G Baxter; K M Frick; D L Price; S J Breckler; A L Markowska; L K Gorman
Journal:  Neuroscience       Date:  1999-03       Impact factor: 3.590

5.  Effects of radiofrequency exposure on the GABAergic system in the rat cerebellum: clues from semi-quantitative immunohistochemistry.

Authors:  A L Mausset; R de Seze; F Montpeyroux; A Privat
Journal:  Brain Res       Date:  2001-08-31       Impact factor: 3.252

6.  Chronic antipsychotic treatment selectively alters nerve growth factor and neuropeptide Y immunoreactivity and the distribution of choline acetyl transferase in rat brain regions.

Authors:  Francesco Angelucci; Luigi Aloe; Susanne H. M. Gruber; Marco Fiore; Aleksander A. Mathé
Journal:  Int J Neuropsychopharmacol       Date:  2000-03       Impact factor: 5.176

7.  Haloperidol administration in humans lowers plasma nerve growth factor level: evidence that sedation induces opposite effects to arousal.

Authors:  L Aloe; A Iannitelli; G Bersani; E Alleva; F Angelucci; P Maselli; L Manni
Journal:  Neuropsychobiology       Date:  1997       Impact factor: 2.328

Review 8.  Atypical antipsychotics: mechanism of action.

Authors:  Philip Seeman
Journal:  Can J Psychiatry       Date:  2002-02       Impact factor: 4.356

9.  Topographic analysis of the innervation of the rat neocortex and hippocampus by the basal forebrain cholinergic system.

Authors:  M McKinney; J T Coyle; J C Hedreen
Journal:  J Comp Neurol       Date:  1983-06-10       Impact factor: 3.215

10.  Chronic treatment with scopolamine and physostigmine changes nerve growth factor (NGF) receptor density and NGF content in rat brain.

Authors:  J Alberch; M Carman-Krzan; M Fabrazzo; B C Wise
Journal:  Brain Res       Date:  1991-03-01       Impact factor: 3.252

View more
  12 in total

1.  Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy.

Authors:  Kiren Ubhi; Chandra Inglis; Michael Mante; Christina Patrick; Anthony Adame; Brian Spencer; Edward Rockenstein; Verena May; Juergen Winkler; Eliezer Masliah
Journal:  Exp Neurol       Date:  2012-01-16       Impact factor: 5.330

2.  Effect of antipsychotics on succinate dehydrogenase and cytochrome oxidase activities in rat brain.

Authors:  Emilio L Streck; Gislaine T Rezin; Luciana M Barbosa; Lara C Assis; Eliane Grandi; João Quevedo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-08-03       Impact factor: 3.000

3.  Simultaneous determination of five antipsychotic drugs in rat plasma by high performance liquid chromatography with ultraviolet detection.

Authors:  Guodong Zhang; Alvin V Terry; Michael G Bartlett
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-05-26       Impact factor: 3.205

Review 4.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

5.  Effects of risperidone and paliperidone pre-treatment on locomotor response following prenatal immune activation.

Authors:  Neil M Richtand; Rebecca Ahlbrand; Paul Horn; Kevin Stanford; Stefanie L Bronson; Robert K McNamara
Journal:  J Psychiatr Res       Date:  2011-03-25       Impact factor: 4.791

6.  Fluoxetine and aripiprazole treatment following prenatal immune activation exert longstanding effects on rat locomotor response.

Authors:  Neil M Richtand; Rebecca Ahlbrand; Paul Horn; Rabindra Tambyraja; Molly Grainger; Stefanie L Bronson; Robert K McNamara
Journal:  Physiol Behav       Date:  2012-02-09

7.  Dopamine D2 receptor plays a role in memory function: implications of dopamine-acetylcholine interaction in the ventral hippocampus.

Authors:  Hiroshige Fujishiro; Hiroyuki Umegaki; Yusuke Suzuki; Shinobu Oohara-Kurotani; Yoko Yamaguchi; Akihisa Iguchi
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

8.  Sensitive liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue.

Authors:  Guodong Zhang; Alvin V Terry; Michael G Bartlett
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-08-17       Impact factor: 3.205

9.  Antipsychotic-induced oxidative stress in rat brain.

Authors:  Márcio R Martins; Fabrícia C Petronilho; Karin M Gomes; Felipe Dal-Pizzol; Emilio L Streck; João Quevedo
Journal:  Neurotox Res       Date:  2008-01       Impact factor: 3.911

10.  Effect of antipsychotic drugs on DISC1 and dysbindin expression in mouse frontal cortex and hippocampus.

Authors:  S Chiba; R Hashimoto; S Hattori; M Yohda; B Lipska; D R Weinberger; H Kunugi
Journal:  J Neural Transm (Vienna)       Date:  2006-02-06       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.